Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 133

First Stem Cell Nerve Therapy Meant to Reverse Paralysis Enters Clinical Trial

It begins with a fall, a crash, or a sudden jolt. In a split second, the spinal cord shatters. For millions, the damage is permanent. But in Shanghai and Suzhou, a group of scientists believes that might soon change.

This May, a biotech startup named XellSmart Biopharmaceutical received rare dual approval from both U.S. and Chinese regulators to launch a Phase I trial for an experimental treatment. The therapy is designed to repair spinal cord injuries using neurons grown in a lab.

The trial, described as the first of its kind, is being led by the Third Affiliated Hospital of Sun Yat-sen University in China. The goal: to test whether specialized nerve cells can be safely implanted into people whose spinal cords were recently injured.

A cell therapy for regenerating broken spinal cord using lab-grown neurons enters human trials for the first time.

Filters inspired by nose hair and nasal mucus promise cleaner air

One of the problems of conventional filters used in homes, businesses and public spaces is their poor performance. They rely on weak van der Waals forces to capture particles like dust and pollen, meaning they let a lot of stuff slip through. Nature, however, does the job a whole lot better.

Drawing inspiration from the , at Chung-Ang University in South Korea designed an air filtration system that mimics the coating nasal hairs.

Plants engineered for optimal biofuel production

Arabidopsis may seem like a simple plant, but at the University of Missouri, plant biochemist Jay Thelen is using it as a powerful model to explore ways to boost oil production—an important step toward creating more sustainable, plant-based energy sources.

To meet the increasing global demand for biofuels, scientists are already modifying to boost the amount of plant oil being produced. That’s because inside the plant, a complex network of metabolic pathways turns sunlight, carbon dioxide (or atmospheric carbon), water and nutrients into vital compounds including oil, the foundational ingredient of biofuel.

Genes give instructions to enzymes, and, in turn, those enzymes help control the plant’s metabolic pathways. But we are only beginning to understand how modifying these genes to produce more oil affects the plant’s other metabolic pathways, which are all interconnected.

Breakthrough gene therapy jab reverses hearing loss in weeks

Researchers also found that the treatment was safe and well-tolerated. Participants did not report any serious adverse reactions in the follow-up period of 6–12 months.

The most common reaction was a reduction in the number of the immune system’s neutrophils, a type of white blood cell.

“OTOF is just the beginning,” Dr Duan said, adding that researchers were working on other common genes behind deafness such as GJB2 and TMC1.

Catalase Activity in the Brain Is Associated with Recovery from Brain Injury in a Piglet Model of Traumatic Brain Injury

Background/Objectives: Traumatic brain injury (TBI) is a global leading cause of disability and death, with millions of new cases added each year. Oxidative stress significantly exacerbates primary TBI, leading to increased levels of intracerebral cell death, tissue loss, and long-term functional deficits in surviving patients. Catalase and superoxide dismutase (SOD) mitigate oxidative stress and play a critical role in dampening injury severity. This study examines the neuroprotective effects of the novel antioxidant alpha lipoic acid-based therapeutic, CMX-2043, on antioxidant enzymes in a preclinical TBI model via various drug administration routes. Methods: Piglets (n = 28) underwent cortical controlled impact to induce moderate–severe TBI and were assigned to placebo (n = 10), subcutaneous CMX-2043 (SQ, 10 mg/kg; n = 9), or intravenous CMX-2043 (IV, 9 mg/kg; n = 9) treatment groups. Treatments began 1 h after TBI induction and continued for 5 days. MRI was performed throughout the study period to evaluate brain recovery. Blood was collected at 1, 7, and 42 days post-TBI, and liver and brain tissues were collected at 42 days post-TBI to measure catalase and SOD activity. Results: CMX-2043 IV-treated piglets showed 46.3% higher hepatic catalase activity than placebo (p = 0.0038), while the SQ group did not show significant changes in hepatic catalase activity compared to placebo. In the brain, SQ-treated piglets had significantly higher catalase activity than both IV (p = 0.0163) and placebo (p = 0.0003) groups (45.8340 ± 3.0855, 36.4822 ± 1.5558, 31.6524 ± 1.3129 nmol/min/mg protein for SQ, IV, and placebo, respectively), while IV-treated piglets did not show significant changes compared to placebo. IV-treated piglets did exhibit 39.3% higher brain SOD activity than placebo (p = 0.0148), while the SQ group did not show a significant change. CMX-2043 treatment did not alter plasma antioxidant enzyme activity during the study period. Importantly, within CMX-2043 treated TBI groups, piglets with significantly decreased lesion volumes, midline shift, and combined swelling and atrophy had better brain recovery, determined by MRI on day 1, 7, and 42 days post-injury TBI, exhibited higher brain catalase activity at 42 days post-injury TBI regardless of administration route, suggesting a link between improved recovery and sustained local catalase activity. Conclusions: This study highlights the impact of administration route on tissue-specific antioxidant responses, with IV administration enhancing liver catalase and brain SOD activity, while SQ administration primarily elevated brain catalase activity. In addition, this study shows an association between increased brain catalase activity and decreased TBI brain lesioning, midline shift, and combined swelling and atrophy, thus emphasizing the role of antioxidant defenses in neuroprotection post-injury.

Looking to study neurological conditions, researchers produce over 400 different types of nerve cells

Nerve cells are not just nerve cells. Depending on how finely we distinguish, there are several hundred to several thousand different types of nerve cells in the human brain, according to the latest calculations. These cell types vary in their function, in the number and length of their cellular appendages, and in their interconnections. They emit different neurotransmitters into our synapses, and depending on the region of the brain—for example, the cerebral cortex or the midbrain—different cell types are active.

When scientists produced from in Petri dishes for their experiments in the past, it was not possible to take their vast diversity into account. Until now, researchers had only developed procedures for growing a few dozen different types of nerve cell in vitro. They achieved this using or by adding signaling molecules to activate particular cellular signaling pathways. However, they never got close to achieving the diversity of hundreds or thousands of different nerve cell types that actually exist.

“Neurons derived from stem cells are frequently used to study diseases. But up to now, researchers have often ignored which precise types of neuron they are working with,” says Barbara Treutlein, Professor at the Department of Biosystems Science and Engineering at ETH Zurich in Basel.

Illuminated sugars show how microbes eat the ocean’s carbon

A team of chemists, microbiologists and ecologists has designed a molecular probe (a molecule designed to detect proteins or DNA inside an organism, for example) that lights up when a sugar is consumed.

In the Journal of the American Chemical Society, they now describe how the probe helps researchers study the microscopic tug-of-war between algae and microbial degraders in the ocean.

“Sugars are ubiquitous in , yet it’s still unclear whether or how can degrade them all,” says Jan-Hendrik Hehemann from the Max Planck Institute for Marine Microbiology and the MARUM—Center for Marine Environmental Sciences, both located in Bremen.

/* */